Shekeab Jauhari
Medical Oncology · Lake Mary, FLNPI 1417394149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,988 of the $2,926 with a category attached, or 67.9%. 28 manufacturers reported payments, led by Pfizer at 33.5% of the total. Reporting peaked in 2020 at $1,123 and has fallen 87.2% since, to $143 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 78 payments — averaging $37.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$980
- AstraZeneca$305
- Johnson & Johnson$207
- Beone Medicines USA, Inc.$143
- Novartis$141
- Genentech USA, Inc.$137
- plus $1K from 22 others
Across 72 payments — averaging $22,917 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.1M
- Eli Lilly$452K
- Bristol Myers Squibb$34K
- Genentech, Inc.$12K
- Exelixis Inc.$8K
What the payments were for
- Speaking & faculty fees$93832%
- Food & beverage$1,98868%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $980 |
| AstraZeneca | 4 | $305 |
| Johnson & Johnson | 10 | $207 |
| Beone Medicines USA, Inc. | 1 | $143 |
| Novartis | 7 | $141 |
| Genentech USA, Inc. | 3 | $137 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $120 |
| Astellas Pharma US Inc | 7 | $113 |
| Eli Lilly | 1 | $94 |
| AbbVie | 5 | $92 |
| Incyte Corporation | 4 | $87 |
| Eisai Inc. | 2 | $56 |
| Seagen Inc. | 3 | $51 |
| Amgen | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Gilead(2 entities) | 2 | $39 |
| Lilly USA, LLC | 3 | $39 |
| Tesaro, Inc. | 1 | $29 |
| Global Blood Therapeutics, Inc. | 2 | $29 |
| Advanced Accelerator Applications | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Sanofi | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $21 |
| GE HealthCare | 1 | $17 |
| Morphosys, US Inc. | 1 | $17 |
| GSK | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,926 in reported general payments places this provider in the 25th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Lake Mary
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.